2026, Insurance and Vaccines - Pharmacy Technician Pulse

Navigating uncertainty: the future of vaccine oversight amid CDC firings

Pharmaceutical Technology

JUNE 25, 2025

GlobalData Healthcare June 25, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Changes to ACIP could result in regulatory uncertainty for vaccine developers and manufacturers. Malone, an early mRNA pioneer, has made unfounded claims regarding the dangers of mRNA vaccines, which have sparked significant public backlash.

Vaccines

Vaccines Packaging Hospitals Communication

Turning Reconciliation into a Revenue Growth Engine

Drug Topics

JUNE 23, 2025

For instance, the MFP is expected to affect approximately 10 drugs in 2026, with the list expanding annually, potentially creating a $22,000 monthly financial impact for average retail pharmacies.

Patient Care

Patient Care Vaccines Specialty Pharmacies Compounding

GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients

Pharmaceutical Technology

JULY 14, 2025

How will RFK Jr’s American dream for vaccines play out? Robert Barrie July 14, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Broader label coverages for Pfizer and Moderna’s vaccines mean they have made in-roads into GSK’s RSV dominant market share. A decision by the FDA is expected in H1 2026.

Labelling

Labelling Vaccines FDA Packaging

FDA approves KalVista’s Ekterly for hereditary angioedema

Pharmaceutical Technology

JULY 7, 2025

How will RFK Jr’s American dream for vaccines play out? KalVista will receive an upfront payment of $11m, with an additional $11m contingent upon achieving a regulatory milestone anticipated by early 2026. In April 2025, KalVista Pharmaceuticals granted Kaken Pharmaceutical the commercialisation rights for sebetralstat in Japan.

FDA

FDA Packaging Communication Hospitals

UK steps up with £1.25bn Gavi vaccine pledge as US funding disappears

Pharmaceutical Technology

JUNE 26, 2025

The UK has confirmed its support for global vaccination by pledging £1.25bn to global vaccine group Gavi while the US will halt funding to the international organisation. The group had set a fundraising target of $11.9bn for its 2026-2030 budget. Credit: speedshutter Photography via Shutterstock.

Vaccines

Vaccines Packaging Communication Hospitals

FDA to review MSD’s doravirine/islatravir NDA for HIV-1

Pharmaceutical Technology

JULY 14, 2025

How will RFK Jr’s American dream for vaccines play out? A target action date of 28 April 2026 has been set under the Prescription Drug User Fee Act (PDUFA). Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma Formulate Faster.

FDA

FDA Packaging Research Laboratories Hospitals

Ultragenyx receives complete response letter for UX111 BLA

Pharmaceutical Technology

JULY 14, 2025

How will RFK Jr’s American dream for vaccines play out? While the CRL will delay the potential approval of UX111 to 2026, we are working with urgency to respond and resubmit.” We have been diligently responding to the recent CMC observations and our priority is to resolve them so that we can resubmit the BLA as soon as possible. “We

Communication

Communication Packaging Hospitals FDA

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Pharmacy Times

JULY 4, 2025

1 For these reasons, the authors conducted this study to evaluate the clinical success and patient outcomes following the mandatory conversion from Humira to a biosimilar because of insurance-related restrictions. Subscribe Now!

Specialty Pharmacies

Specialty Pharmacies Hospitals Compounding Pharmacies Vaccines

Antares Therapeutics gains $177m for cancer medicines development

Pharmaceutical Technology

JUNE 11, 2025

June 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The company intends to introduce its inaugural product candidate into clinical trials by 2026. The company is progressing several programmes, intending to introduce its inaugural product candidate into clinical trials by 2026.

Communication

Communication Hospitals Packaging Insurance

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Pharmaceutical Technology

JULY 1, 2025

How will RFK Jr’s American dream for vaccines play out? Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

FDA

FDA Packaging Communication Hospitals

LEO Pharma secures rights to Boehringer’s Spevigo for $105m

Pharmaceutical Technology

JULY 15, 2025

How will RFK Jr’s American dream for vaccines play out? Danish dermatology leader LEO Pharma has bought the rights to Boehringer Ingelheim’s psoriasis drug Spevigo (spesolimab) for €90m ($105m), strengthening its portfolio ahead of a possible public listing in 2026. Give your business an edge with our leading industry insights.

JCR Pharma and Alexion partner on JUST-AAV gene therapy platform

Pharmaceutical Technology

JULY 9, 2025

How will RFK Jr’s American dream for vaccines play out? The financial impact of this agreement on JCR’s consolidated results for the fiscal year ending 31 March 2026 has already been included in the current earnings forecast. JUST-AAV is a proprietary platform technology that employs modified AAV vectors.

Packaging

Packaging Communication Hospitals Insurance

Vertex and NHS England agree reimbursement for Alyftrek

Pharmaceutical Technology

JULY 15, 2025

How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

Pharmaceutical Technology

JUNE 16, 2025

However, Blincyto’s loss of exclusivity in Europe (2025) and the US (2026) is expected to significantly reduce its future sales. According to GlobalData’s analyst consensus forecast, surovatamig’s global sales are projected to reach $138 million by 2031, compared to $1.7 billion for Blincyto. Sign up for our daily news round-up!

Labelling

Labelling Communication Vaccines Hospitals

Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access

pharmaphorum

JANUARY 21, 2022

And as with many healthcare challenges, it is an issue that has been brought into sharp focus by COVID-19, during which we have seen huge investments in ground-breaking vaccines, quickly followed by inequities in access. Transformative, lifesaving products are available at increasingly high and unsustainable prices.

Insurance

Insurance Vaccines

STAT+: Budget negotiations heat up as ACA subsidy extension, BIOSECURE get dropped

STAT

DECEMBER 10, 2024

Democrats floated the idea of extending the subsidies through 2026 in a year-end deal, and paying for it with a budgetary maneuver that would theoretically extend budget cuts that haven’t actually been implemented, as my colleague Rachel Cohrs Zhang reported. million people would lose coverage annually without the tax credits.

Insurance

Insurance Vaccines

Health Canada extends Evkeeza approval for children with HoFH

Pharmaceutical Technology

JULY 15, 2025

How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.

Average cost of Farxiga on Medicare

The Checkup by Singlecare

JUNE 6, 2024

That’s why many Medicare and health insurance plans cover the drug. Farxiga was selected as one of the first 10 drugs for negotiated prices and should be available at lower prices starting in 2026. That’s why most insurance and Medicare Part D plans cover Farxiga. RELATED: How much is Farxiga without insurance?

Insurance

Insurance Hospitals Pharmaceutical Companies Pharmaceutical Companies

Sino Biopharma spends $951m to acquire China-based LaNova Medicines

Pharmaceutical Technology

JULY 15, 2025

How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.

Jardiance cost with Medicare

The Checkup by Singlecare

JUNE 6, 2024

Fortunately, most Medicare and commercial insurance plans cover Jardiance. Original Medicare Parts A and B provide health insurance for inpatient and outpatient health services respectively, among other services. That means a new, negotiated price for Jardiance will be effective in 2026.

Insurance

Insurance Hospitals Vaccines Pharmaceutical Companies

Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults

Pharmaceutical Technology

JUNE 13, 2025

Robert Barrie June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook mRESVIA is the second approved product in the US for Moderna, along with its Covid-19 vaccine Spikevax. Until now, the vaccine was licensed for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years and older.

Vaccines

Vaccines FDA Labelling Communication

WHO endorses Gilead’s Yeztugo for HIV prevention

Pharmaceutical Technology

JULY 14, 2025

How will RFK Jr’s American dream for vaccines play out? The WHO says that the vaccine offers a highly effective, long-acting alternative to daily oral pills and other shorter-acting options. The approval of Yeztugo was hailed as a historical breakthrough by HIV experts and charities. Sign up for our daily news round-up!

Vaccines

Vaccines Packaging Hospitals Communication

How Will the Prescription Drug Provisions in the Inflation Reduction Act Affect Medicare Beneficiaries?

BuzzRx

AUGUST 30, 2022

The Inflation Reduction Act will allow the government to negotiate lower prescription drug costs for some of the highest-priced, covered drugs between 2026 and 2029 and beyond. million who received the shingles vaccine. This will benefit people with Medicare health care coverage and potentially also those with private health insurance.

Vaccines

Vaccines Insurance Packaging Immunization

STAT+: Pharmalittle: We’re reading about Trump’s drug-pricing plan, a Moderna change of plans, and more

STAT

MAY 21, 2025

do not have a single price — different commercial insurers, Medicaid, and Medicare may all face different costs. Moderna has withdrawn an application seeking approval for its flu and Covid combination vaccine candidate after discussions with the U.S. Drugs sold in the U.S. Food and Drug Administration , Reuters notes.

Vaccines

Vaccines FDA Insurance

Pharmacy Technician Pulse

Navigating uncertainty: the future of vaccine oversight amid CDC firings

Turning Reconciliation into a Revenue Growth Engine

Trending Sources

GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients

FDA approves KalVista’s Ekterly for hereditary angioedema

UK steps up with £1.25bn Gavi vaccine pledge as US funding disappears

FDA to review MSD’s doravirine/islatravir NDA for HIV-1

Ultragenyx receives complete response letter for UX111 BLA

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Antares Therapeutics gains $177m for cancer medicines development

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

LEO Pharma secures rights to Boehringer’s Spevigo for $105m

JCR Pharma and Alexion partner on JUST-AAV gene therapy platform

Vertex and NHS England agree reimbursement for Alyftrek

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL

Oslo Medicines Initiative asks how to balance innovation incentivisation with security of access

STAT+: Budget negotiations heat up as ACA subsidy extension, BIOSECURE get dropped

Health Canada extends Evkeeza approval for children with HoFH

Average cost of Farxiga on Medicare

Sino Biopharma spends $951m to acquire China-based LaNova Medicines

Jardiance cost with Medicare

Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults

WHO endorses Gilead’s Yeztugo for HIV prevention

How Will the Prescription Drug Provisions in the Inflation Reduction Act Affect Medicare Beneficiaries?

STAT+: Pharmalittle: We’re reading about Trump’s drug-pricing plan, a Moderna change of plans, and more

Stay Connected